Novocure and Verastem launch joint pancreatic cancer trial with TTFields and KRAS inhibitor
Novocure (NVCR) and Verastem Oncology (VSTM) have signed a collaboration and supply agreement to test Tumor Treating Fields therapy together with chemotherapy and Verastem’s oral KRAS G12D inhibitor VS‑7375 in locally advanced pancreatic cancer. The trial will enroll about 25 patients and is slated to begin enrolling in 2027. Novocure will fund and manage the study while Verastem will provide the investigational drug.
Why it matters
The companies say the combination could create a new treatment option for a cancer with very low survival rates, potentially expanding Novocure’s pipeline and future revenue streams. The agreement also adds a development partner for Verastem’s KRAS inhibitor, which may accelerate its clinical progress.
Key facts
- 1Novocure and Verastem entered a clinical trial collaboration and supply agreement to evaluate TTFields therapy with chemotherapy and VS‑7375 for locally advanced pancreatic cancer. stocktitan.net
- 2The trial will enroll approximately 25 patients. stocktitan.net
- 3Enrollment is expected to begin in 2027. stocktitan.net
- 4Novocure will manage and fund the clinical trial operations. stocktitan.net
- 5Verastem will supply the investigational drug VS‑7375 for the study. stocktitan.net
- 6The combination treatment will include gemcitabine, nab‑paclitaxel, TTFields therapy, and VS‑7375. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.